Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

CytomX Therapeutics' innovative cancer therapies show promise with the CX-2051 and CX-801 trials. Explore the potential of ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Study to ...

The Trump administration on Tuesday eliminated 22 mRNA vaccine development projects for COVID-19 and bird flu, a stark shift ...

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...

Additionally, a baseline immune response to GP2 was observed before any treatment with GP2 in both HLA-A*02 and non-HLA-A*02 arms. These two immune responses were also observed in the Phase 2b ...

The trial demonstrated a 38% overall response rate and a 17.2% complete response rate, indicating both durability and depth of response, with efficacy observed in both viral and non-viral diseases.

A new study reveals that simply seeing a visibly “infectious” figure can set off a chain reaction in the brain’s ...

Summary: Unlike most tissues, the retina doesn’t summon neutrophils—the body’s typical first responders—when injured. Instead, microglia, the brain’s resident immune cells, handle photoreceptor damage ...